Aptorum Group Limited received a Nasdaq non-compliance notification, granting 180 days to regain compliance with listing requirements.
Quiver AI Summary
Aptorum Group Limited has announced it received a notification from Nasdaq stating it is non-compliant with the minimum bid price requirement of $1 per share, as outlined in Nasdaq Listing Rule 5550(a)(2). The notification, dated March 5, 2026, does not affect the current listing or trading of its shares. The company has been granted a 180-calendar-day grace period, until September 1, 2026, to regain compliance and plans to explore options to do so, which may include a reverse stock split. Aptorum Group is dedicated to maintaining its Nasdaq listing and will take necessary measures to comply.
Potential Positives
- Aptorum Group Limited has been granted a 180-calendar-day grace period to regain compliance with Nasdaq's minimum bid price requirement, allowing the company time to strategize and implement necessary changes.
- The company is proactive in addressing the compliance issue by evaluating all available options, demonstrating a commitment to maintaining its Nasdaq listing.
Potential Negatives
- Aptorum Group Limited has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, which poses a threat to its continued listing on the stock exchange.
- The company is facing a 180-day grace period to regain compliance, indicating ongoing financial challenges that could impact investor confidence.
- Possible measures to restore compliance, such as a reverse stock split, may lead to dilution of shareholder value and could negatively affect market perception of the company's financial health.
FAQ
What is the recent Nasdaq notification received by Aptorum Group Limited?
Aptorum Group Limited received a notification regarding non-compliance with the minimum bid price requirement of $1 per share.
How long does Aptorum Group have to regain compliance?
The company has been granted a 180-calendar-day grace period until September 1, 2026, to regain compliance.
Will Aptorum's listing and trading be affected immediately?
No, the notification does not immediately affect the listing or trading of Aptorum Group's shares on Nasdaq.
What measures might Aptorum Group consider to restore compliance?
The company may consider options such as a reverse stock split to restore compliance with Nasdaq requirements.
What is Aptorum Group Limited's focus?
Aptorum Group Limited is focused on discovering, developing, and commercializing therapeutic assets for unmet medical needs.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$APM Revenue
$APM had revenues of $73.7M in Q2 2025. This is an increase of 5.68% from the same period in the prior year.
You can track APM financials on Quiver Quantitative's APM stock page.
$APM Hedge Fund Activity
We have seen 5 institutional investors add shares of $APM stock to their portfolio, and 2 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC added 115,584 shares (+inf%) to their portfolio in Q4 2025, for an estimated $122,519
- GEODE CAPITAL MANAGEMENT, LLC removed 37,449 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $75,646
- TWO SIGMA INVESTMENTS, LP added 17,411 shares (+inf%) to their portfolio in Q4 2025, for an estimated $18,455
- MORGAN STANLEY added 13,300 shares (+inf%) to their portfolio in Q4 2025, for an estimated $14,098
- UBS GROUP AG added 2,247 shares (+inf%) to their portfolio in Q4 2025, for an estimated $2,381
- BNP PARIBAS FINANCIAL MARKETS added 400 shares (+inf%) to their portfolio in Q4 2025, for an estimated $424
- CITIGROUP INC removed 277 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $293
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
Hong Kong, March 06, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM), a leading Biotechnology company, today announced that it has received a notification from the Nasdaq Stock Market LLC dated March 5, 2026 regarding non-compliance with the minimum bid price requirement of $1 per share, as per Nasdaq Listing Rule 5550(a)(2).
The notification does not immediately affect the listing or trading of the company’s shares on Nasdaq. Aptorum Group Limited has been granted a 180-calendar-day grace period, until September 1, 2026, to regain compliance with the noted listing requirement.
During this period, Aptorum Group Limited intends to evaluate all available options to restore compliance, including, if necessary, a reverse stock split. The company is committed to maintaining its Nasdaq listing and will take all reasonable measures to achieve compliance within the stipulated time frame.
About Aptorum Group Limited
Aptorum Group Limited is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. These statements reflect the company’s current expectations and projections about future events and are based on assumptions. Actual results may differ materially from those projected.
For further information, please contact: [email protected]
